Kiwi Biosciences develops novel, patent-pending enzymes embedded in food and supplements to aid digestion. Their flagship product, FODZYME®, is an enzyme solution designed to break down problematic FODMAP carbohydrates, common triggers for digestive discomfort. This technology allows individuals with sensitive guts to consume previously avoided foods without experiencing symptoms like bloating or gas.
Funding
$1.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many individuals experience digestive discomfort, such as gas and bloating, due to FODMAPs (fermentable oligosaccharides, disaccharides, monosaccharides, and polyols) in their diet. These carbohydrates are poorly absorbed in the small intestine, leading to fermentation in the gut.
Solution
Kiwi Bio has developed FODZYME®, a patent-pending enzyme supplement designed to alleviate digestive issues caused by FODMAPs. FODZYME® contains enzymes that break down fructan, galacto-oligosaccharides, and lactose, three common FODMAPs known to trigger gut symptoms. By breaking down these complex carbohydrates into smaller, more digestible molecules, FODZYME® reduces fermentation and osmotic effects in the gut, thereby minimizing symptoms like gas, bloating, and abdominal pain.
Target Audience
The primary target audience is individuals with sensitive guts or Irritable Bowel Syndrome (IBS) who experience digestive discomfort after consuming high-FODMAP foods.
Features
- Contains enzymes that specifically target and break down fructan, GOS, and lactose.
- Designed to be sprinkled on or mixed with high-FODMAP meals.
- Reduces excessive fermentation by gut microorganisms.
- Minimizes osmotic effects that can lead to digestive symptoms.